Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol
By Chris Wack
Esperion shares were up 16% to $2.67 after the company said Friday the U.S. Food and Drug Administration approved broad new label expansions for Nexletol bempedoic acid tablets and Nexlizet bempedoic acid and ezetimibe tablets.
The stock closed Friday's session up 9% after the news came out, and is now up 66% in the past 12 months.
Esperion said the approval was based on positive data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients.
The enhanced labels support the use of Nexletol and Nexlizet either alone or in combination with statins. They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.
The company said its pending label expansions in Europe remain on track, with a positive opinion received from the Committee for Medicinal Products for Human Use on Thursday. Esperion anticipates a final determination by the European Medicines Agency in the second quarter.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 25, 2024 11:18 ET (15:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying